Regorafenib in gastrointestinal stromal tumors.
Author(s): Sirohi B(1), Philip DS, Shrikhande SV.
Affiliation(s): Author information:
(1)Department of Medical Oncology, Tata Memorial Centre, Mumbai, India.
Publication date & source: 2014, Future Oncol. , 10(9):1581-7
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of
the GI tract and constitute less than 1% of all digestive tract tumors--the
stomach is the most common site. Regorafenib is a multi-tyrosine kinase inhibitor
with regulatory approvals granted for colorectal cancers and GIST. The US FDA
granted approval for the use of regorafenib in February 2013 in patients with
advanced GIST for those who had failed on imatinib and sunitinib. This was based
on a pivotal Phase III double-blind placebo controlled randomized trial that
showed that there was a significant improvement in progression-free survival for
patients on regorafenib.
|